Explore more publications!
Oklahoma Healthcare Wire
Got News to Share?

Oklahoma Healthcare Wire: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Oklahoma Healthcare Wire.

October 2025

Mo Tu We Th Fr Sa Su
1 2 3 4 5
6 7 8 9 10 11 12
13 14 15 16 17 18 19
20 21 22 23 24 25 26
27 28 29 30 31

November 2025

Mo Tu We Th Fr Sa Su
1 2
3 4 5 6 7 8 9
10 11 12 13 14 15 16
17 18 19 20 21 22 23
24 25 26 27 28 29 30

December 2025

Mo Tu We Th Fr Sa Su
1 2 3 4 5 6 7
8 9 10 11 12 13 14
15 16 17 18 19 20 21
22 23 24 25 26 27 28
29 30 31

Press releases published on December 18, 2025

Sangamo Therapeutics Initiates Rolling Submission of BLA to U.S. FDA for ST-920 in Fabry Disease
December 18, 2025

Sangamo Therapeutics Initiates Rolling Submission of BLA to U.S. FDA for ST-920 in Fabry Disease

Indeterminate GlobeNewswire
Numab Therapeutics Achieves Milestone in Second Collaboration Project with Boehringer Ingelheim
December 18, 2025

Numab Therapeutics Achieves Milestone in Second Collaboration Project with Boehringer Ingelheim

Indeterminate GlobeNewswire
First Patient Dosed in SAB BIO’s SAFEGUARD Clinical Trial of SAB-142 for the Treatment of Stage 3 T1D
December 18, 2025

First Patient Dosed in SAB BIO’s SAFEGUARD Clinical Trial of SAB-142 for the Treatment of Stage 3 T1D

Indeterminate GlobeNewswire
Pacira Biosciences Joins PROBE Consortium to Transform Osteoarthritis Research and Care
December 18, 2025

Pacira Biosciences Joins PROBE Consortium to Transform Osteoarthritis Research and Care

Indeterminate GlobeNewswire
RESTEM to Participate in the 15th LifeSci Partners Corporate Access Event Held During the J.P. Morgan Healthcare Conference in January 2026
December 18, 2025

RESTEM to Participate in the 15th LifeSci Partners Corporate Access Event Held During the J.P. Morgan Healthcare Conference in January 2026

Indeterminate GlobeNewswire
Larimar Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
December 18, 2025

Larimar Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

Indeterminate GlobeNewswire
SUO-CTC and CG Oncology Announce the Second Annual Non-Muscle Invasive Bladder Cancer (NMIBC) Research Fellowship Award
December 18, 2025

SUO-CTC and CG Oncology Announce the Second Annual Non-Muscle Invasive Bladder Cancer (NMIBC) Research Fellowship Award

Indeterminate GlobeNewswire
Cocrystal Pharma Receives IRB Approval from Emory University School of Medicine for Phase 1b Human Challenge Study with CDI-988 for Prevention and Treatment of Norovirus
December 18, 2025

Cocrystal Pharma Receives IRB Approval from Emory University School of Medicine for Phase 1b Human Challenge Study with CDI-988 for Prevention and Treatment of Norovirus

Indeterminate GlobeNewswire
Replimune to Present at the 44th Annual J.P. Morgan Healthcare Conference
December 18, 2025

Replimune to Present at the 44th Annual J.P. Morgan Healthcare Conference

Indeterminate GlobeNewswire
Beacon Therapeutics to Present at the 44th Annual JP Morgan Healthcare Conference
December 18, 2025

Beacon Therapeutics to Present at the 44th Annual JP Morgan Healthcare Conference

Indeterminate GlobeNewswire
CorMedix Therapeutics Announces Positive Data From Ongoing Real World Evidence Study of DefenCath
December 18, 2025

CorMedix Therapeutics Announces Positive Data From Ongoing Real World Evidence Study of DefenCath

Indeterminate GlobeNewswire
Ovid Therapeutics Reports Phase 1 Results for the First-Ever Direct Activator of Potassium-Chloride Cotransporter 2 (KCC2), OV350 Intravenous (IV)
December 18, 2025

Ovid Therapeutics Reports Phase 1 Results for the First-Ever Direct Activator of Potassium-Chloride Cotransporter 2 (KCC2), OV350 Intravenous (IV)

Indeterminate GlobeNewswire
Revolution Medicines Announces First Patient Randomized in the RASolute 304 Clinical Trial of Daraxonrasib in Resectable Pancreatic Ductal Adenocarcinoma Following Adjuvant Chemotherapy
December 18, 2025

Revolution Medicines Announces First Patient Randomized in the RASolute 304 Clinical Trial of Daraxonrasib in Resectable Pancreatic Ductal Adenocarcinoma Following Adjuvant Chemotherapy

Indeterminate GlobeNewswire
Final, 247th participant randomized and commences treatment in Actinogen’s XanaMIA pivotal phase 2b/3 Alzheimer’s trial
December 18, 2025

Final, 247th participant randomized and commences treatment in Actinogen’s XanaMIA pivotal phase 2b/3 Alzheimer’s trial

Indeterminate GlobeNewswire
Catheter Precision (VTAK) Announces Expansion of LockeT into an Eighth European Country Since Receipt of CE Mark
December 18, 2025

Catheter Precision (VTAK) Announces Expansion of LockeT into an Eighth European Country Since Receipt of CE Mark

Indeterminate GlobeNewswire
Werewolf Therapeutics Announces Pipeline and Business Updates
December 18, 2025

Werewolf Therapeutics Announces Pipeline and Business Updates

Indeterminate GlobeNewswire
Salarius Pharmaceuticals Announces Planned Corporate Name and Ticker Symbol Change to Decoy Therapeutics, Reflecting Strategic Pivot to Next-Generation Antiviral and Peptide-Conjugate Platform
December 18, 2025

Salarius Pharmaceuticals Announces Planned Corporate Name and Ticker Symbol Change to Decoy Therapeutics, Reflecting Strategic Pivot to Next-Generation Antiviral and Peptide-Conjugate Platform

Indeterminate GlobeNewswire
Microbix Reports Results for Q4 and Fiscal 2025
December 18, 2025

Microbix Reports Results for Q4 and Fiscal 2025

Indeterminate GlobeNewswire
Appili Therapeutics Announces Closing of First Tranche of Non-Brokered Private Placement
December 18, 2025

Appili Therapeutics Announces Closing of First Tranche of Non-Brokered Private Placement

Indeterminate GlobeNewswire
Enable Injections Announces Regulatory Approval in Saudi Arabia for the EMPAVELI® Injector based on enFuse® Technology
December 18, 2025

Enable Injections Announces Regulatory Approval in Saudi Arabia for the EMPAVELI® Injector based on enFuse® Technology

Indeterminate GlobeNewswire
Show More

Share us

on your social networks:
Facebook Facebook LinkedIn LinkedIn
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms & Conditions